<DOC>
	<DOCNO>NCT01702467</DOCNO>
	<brief_summary>The current study examine safety , tolerability , plasma pharmacokinetics ( PK ) , plasma pharmacodynamics ( PD ) single-doses GSK2647544.The study conduct randomize , single-blind , placebo control , 4-way crossover single oral ascend dose design 2 independent cohort , eight healthy male subject cohort . Each potential subject undergo Screening visit , Treatment Phase Follow-up visit .</brief_summary>
	<brief_title>Safety , Tolerability , Pharmacokinetics Pharmacodynamics Single , Oral Escalating Doses GSK2647544 Healthy Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<criteria>Healthy male 18 55 year age , inclusive Healthy determine responsible experienced physician aspartate aminotransferase ( AST ) , Alanine transaminase ( ALT ) , alkaline phosphatase bilirubin &lt; = 1.5xUpper Limit Normal ( ULN ) Average triplicate QTcB value average triplicate QTcF value must &lt; 450 millisecond ( msec ) Body weight &gt; 50 kg ( 110 pound ) body mass index ( BMI ) 19 30 Male subject female partner childbearing potential must agree use one contraception method Capable give write informed consent Those LpPLA2 activity &lt; =20 nanomole/minute/milliliter ( mL ) ( subject 2 known birth parent least 50 % Japanese , Chinese , Korean ancestry ) History asthma , anaphylaxis anaphalactoid reaction , severe allergic response History hypercoagulable state history thrombosis A history biliary tract disease include history liver disease elevate liver function test know unknown etiology Positive Human immunodeficiency virus ( HIV ) , Hepatitis B Hepatitis C screen History regular use tobacco nicotinecontaining product within three month study and/or positive breath CO screen History alcohol consumption exceed , average , 21 drinks/week men ( 1 drink = 100 mL wine 240 mL beer 30 mL hard liquor Australia ) within 6 month first dose study medication Positive urine drug positive breath alcohol test screen admission Clinical Research Unit Unable refrain use prescription nonprescription drug vitamin within 7 day 5 halflives ( whichever longer ) prior administration study Unable refrain use dietary/herbal supplement include ( limited ) St. John 's wort , kava , ephedra ( huang ) , gingko biloba , DHEA , yohimbe , saw palmetto , ginseng red yeast rice within 14 day prior treatment study medication Treatment investigational drug within 30 day 5 halflives ( whichever longer ) prior dose Unable refrain consumption grapefruit grapefruit juice within 7 day prior first dose study medication For male subject , unwillingness abstain sexual intercourse pregnant lactate woman unwillingness use condom plus partner use highly effective contraceptive engage sexual intercourse woman could become pregnant discharge study Donation blood excess 500 mL within 56 day prior dose History sensitivity heparin heparininduced thrombocytopenia Subjects , investigator 's judgement , pose significant suicide risk . Evidence serious suicide risk may include history suicidal behaviour and/or suicidal ideation type 4 5 CSSRS last 6 month</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Lp-PLA2</keyword>
	<keyword>Alzheimer 's disease</keyword>
</DOC>